R. Bryan Bell, MD, DDS, FACS, FRCS(Ed)

I am deeply honored to succeed Dr. Urba & I am committed to building upon his legacy of transformational  immuno-oncology research & a world-class cancer center dedicated to translating the next generation of immunotherapies from lab bench to the bedside. @ChilesResearch

⁦@providence⁩ receives esteemed NIH grant for ‘paradigm shift’ in head and neck cancer treatments providence.org/news/uf/693008…

@HeartOTXHeartMD No advice- just happy birthday, old friend. (No pun intended 🙂)

For my 60th birthday, give me some random advice. Not about anything in particular. Just random advice. #PoppyTweets

Grateful for the warm welcome & outstanding exchange with @JosephMCurryMD & the team at the @JeffersonUniv. Inspiring to connect around our shared mission to advance translational science & deliver cutting-edge cancer care. Looking forward to continued collaboration @providence

The FDA has approved teclistamab (BCMA×CD3 bispecific) + daratumumab (CD38)—bringing powerful immune-based therapy and another inflection point in survival outcome. A major step toward durable remissions—and potentially functional cure. #FinishCancer @providence

Real-world data shows WGS drives treatment decisions and improves outcomes beyond standard panels. It’s time for payers & legislators to evolve coverage & privacy policy to support comprehensive profiling & ensure equitable access to precision oncology. nature.com/articles/s4159…

@Providence continues to lead at the intersection of AI and cancer care. New @CellPressNews study led by Carlo Bifulco: GigaTIME (with @Microsoft + @UW) turns routine pathology into virtual spatial proteomics. A new model for discovery. @satyanadella: lnkd.in/gH23Kevy

We’ve trained a multimodal AI model to turn routine pathology slides into spatial proteomics, with the potential to reduce time and cost while expanding access to cancer care.

Honored to present our abstract on the Surgical Results from KEYNOTE-689 at the Multidisciplinary Head & Neck Cancer Conference in Palm Desert this week. MPR, <50% RVT=improved survival! @AHNSinfo @ASTRO_org @ASCO @sitcancer @Merck @providence astro.org/meetings-and-e…

Excited to share the final publication in The Lancet of our phase 3 GORTEC 2018-01 (NIVOPOST-OP) trial results. We hope these results will support changes in clinical practice and future guideline updates. @PBlanchardMD @DrMLChua @GorphePhilippe thelancet.com/journals/lance…

As 2025 comes to a close, I’m excited to share our Newsletter, which reflects on key milestones from @ChilesResearch in 2025 & looks ahead to what’s next as we continue to push the boundaries of what’s possible in cancer care & research @Providence. blog.providence.org/regional-blog-…

As we near the end of 2025, I am pleased to share my reflections on the resilience, innovation & achievements of our clinical, program & research teams at @Providence & @ChilesResearch With gratitude and best wishes for a happy holiday season. sway.cloud.microsoft/7fOrPrIEwSUgxy…

Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling - pushing for reflexive genomic sequencing for all tumor types @providence @ChilesResearch ascopubs.org/doi/10.1200/OP…

On this #VeteransDay, thinking of all the veterans and active service members who have served our nation with courage, sacrifice and unwavering dedication, including my father & grandfather who served in WWII and beyond. Thank you for your service.

Congratulations Robert Saddawi-Konefka (@rsaddawi) on a well deserved @sitcancer Presidential Award! 👏Intact LNs are crucial for tumor response with immunotherapy & LN-sparing neoadjuvant SABR + IO prior to surgery is a potentially paradigm-shifting approach for HNSCC. #SITC2025

European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS ≥1) ⁦@Merck⁩ merck.com/news/european-…

Great discussion ⁦⁦@ChilesResearch⁩ Lab Meeting today ⁦with Dr. Matthew Taylor reviewing remarkable progress in translating his Fas Ligand antibody from bench to bedside- from preclinical development and IND-enabling studies to first in human phase 1 clinical trial.🎃👻

@BrennanSurgeon @RoyalFamily Congratulations Peter! Well done.

Overwhelmed to receive this Warrant of Appointment in the post today, signed by the King and Queen 🇬🇧 I started this human factors & patient safety journey after my father had suffered several preventable medical errors Just wish he was alive now to see what we've achieved 😢

Friday October 26, 2025 was a bittersweet day for @ChilesResearch: It marked the last lab meeting lecture from our esteemed colleague & friend, Michael Gough; and served as a prelude to his and Dr. Marka Crittenden's planned retirement later this year. linkedin.com/posts/r-bryan-…

Forward-looking uveal melanoma signal delivered by @DrSapnaPatel : PRAME-directed TCR (IMA203) hit 67% ORR (10/15) with tumor shrinkage in 16/16; median DOR 11 mo. #ESMO25 #UvealMelanoma @myESMO @Annals_Oncology @OncoAlert @OncLive @OncBrothers